UPC CoA 464/2024

Vor dem UPC: Meril Group (60 Verfahren)·Edwards Lifesciences Group (57 Verfahren)

• 2025-11-25
  Appeal RoP220.1Öffentlich

  Zusammenfassung: The Court of Appeal dismissed the Meril companies' appeals against the revocation and counterclaim revocation decisions and Edwards' appeal against the infringement decision, upholding the patent EP 3 646 825 (heart valve). Key rulings: (I–VIII) All revocation and counterclaim appeals rejected; Meril bears 60% of Edwards' costs in the revocation proceedings and Edwards bears 40% of Meril's costs. (IX–X) The infringement decision was partially set aside: the injunction and preliminary damages order do not extend to XL devices (30.5mm and 32mm) that had not been scheduled for implantation in a patient by 15 November 2024. Preliminary damages reduced to not exceed €363,000 for Meril India and Meril Germany. The value of the proceedings is €8,000,000.

  Rechtsfragen anzeigen (6)

  • Competence and same-parties rule (Art. 33(4) UPCA)
  • Admissibility of application to amend patent (R. 49.2, 50.2 RoP)
  • Claim construction
  • Inventive step
  • Scope of injunction (XL devices)
  • Preliminary damages
• 2024-09-06
  Öffentlich

  Zusammenfassung: The Court of Appeal issued a procedural order in related appeals by Meril entities against Edwards Lifesciences, consolidating multiple appeals and addressing case management for the parallel infringement and counterclaim for revocation proceedings before the Central Division Paris.

  Rechtsfragen anzeigen (4)

  • Consolidated appeals
  • Case management
  • Counterclaim for revocation
  • Transcatheter heart valve